alexa Abstract | Evaluation of Anti-Mycobacterial activity of the Siddha medicine Singi Chenduram against Multi-drug resistant tuberculosis using Luciferase Reporter Phage assay

Journal of Chemical and Pharmaceutical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Original Articles Open Access

Abstract

Multidrug-resistant tuberculosis (MDR-TB) caused by mycobacterium tuberculosis becomes a global life threatening issue in many developing countries including India. Treatment of MDR-TB with second line anti tubercular drugs is associated with lot of side effects which includes hepatitis, depression and hallucinations. Siddha system of medicine has wide choice of therapeutic formulations which offers ailment against dreadful infectious like TB.As an objective of exploring alternate therapy for the clinical management of MDR-TB with less or no side effects the present investigation aimed at evaluating the anti-mycobacterial activity of the siddha drug Singi Chenduram (SC) using Luciferase Reporter Phage assay. In-vitro anti-mycobacterial activity evaluation of SC carried out at the concentration of 100 and 500μg/ml against standard strains of M. tuberculosis H37Rv, clinical isolates of M. tuberculosis strains resistant to first line anti-TB drugs (Streptomycin (S), Isoniazid (H), Rifampicin (R) and Ethambutol (E)) in comparison with marketed standard Rifampicin 2μg/ml. The result obtained from the study clearly reveals that the drug SC at both the concentration of 100 and 500μg/ml shows significant percentage reduction in relative light units (RLU) which is a marker indication of its efficacy against. Hence form the study it was concluded that the drugs like SC from the siddha system of Indian traditional medicine will provides clinically significant results in treating MDR-TB and further has to be ascertained by proper clinical evaluation in the infected subjects.

To read the full article Peer-reviewed Article PDF image

Author(s): K Rajamaheswari M Pitchiah Kumar K Arunachalam

Keywords

MDR-TB, Singi Chenduram, Siddha drug, Luciferase Reporter Phage assay, M. tuberculosis H37Rv, Rifampicin, Anti-Mycobacterial

 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords